| EBITDA Margin: guided vs achieved | 5.00% achieved Guided 5.00%; confirmed by management |
|---|---|
| Management target | Revenue 23.0% FY27 |
| Revenue growth | 38.2% YoY growth, driven by 19.6% organic and 20.4% inorganic gains. |
|---|---|
| Margins | Structural expansion; EBITDA margin hit 5% due to scale and MedTech. |
| Demand visibility | Strong; IPM growing double digits led by volume across all therapy areas. |
| Management confidence | High; confident in organic scalability and achieving full-year targets early. |
Growth
Revenue grew 40% on a like-for-like basis; organic growth was 19.6% while inorganic contributions from past acquisitions added 20.4%.
Outlook
Management maintains FY27 revenue growth guidance of 23% excluding new acquisitions and a 50% EBITDA-to-operating cash flow conversion target.
Risks
High reliance on past M&A for growth; significant minority interest leakage (27% of profit) via non-wholly owned subsidiaries.
Last quarter's promises, checked
Delivered
- Guided 30% LFL Revenue Growth → delivered 31.5% (= BEAT)
- Guided 4% EBITDA Margin → delivered 4% (= BEAT)
- Guided 50% EBITDA-to-OCF conversion → delivered 104.6cr OCF on 86cr Q4 EBITDA (= BEAT)
Partly delivered
- Guided 25-27% Minority Interest leakage → delivered 27% in current Q1 (= PARTIAL)
Earnings Call Transcript filed with BSE, NSE: ENTERO. Summary written with AI assistance from the document.
Entero Healthcare Solutions Ltd: key numbers
- Share price
- ₹1,733.10
- Market cap
- ₹7,543 Cr
- Revenue (annual)
- ₹6,591 Cr
- Net profit (annual)
- ₹115.0 Cr
- P/E (TTM)
- 60.1×Sector 53.1×
- Promoter holding
- 52.40%-0.02% QoQ
- FII holding
- 4.36%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Entero Healthcare Solutions Ltd
All →Entero Healthcare Solutions Capital Structure Change
Surbhi Singh (Prasid Uno Family Trust), a non-promoter, sold 21.30 lakh Entero Healthcare shares via bulk/block deals. Stake fell from 7.94% to 3.05%; no transaction value disclosed.
Entero Healthcare Solutions Legal & Regulatory
Entero Healthcare Solutions reported a GST penalty of Rs. 0.13 Crore imposed on its subsidiary, ACE Cardiopathy Solutions, for non-generation of an E-Invoice.
- Value
- ₹0.13 Cr
Entero Healthcare Solutions Other Announcement
Entero Healthcare Solutions Ltd filed its quarterly shareholding pattern for the period ended March 31, 2026, as per regulatory requirements.
Entero Healthcare Solutions Capital Structure Change
Prasid Uno Family Trust acquired 10,88,500 shares (2.50%) of Entero Healthcare Solutions Ltd via a block deal. Post-transaction, their total stake is 6.93%.
Entero Healthcare Solutions Management Change
Entero Healthcare Solutions announced the completion of the tenure of Non-Executive Independent Director Mr. Rajesh Shashikant Dalal, effective from August 24, 2026.
Entero Healthcare Solutions Annual General Meeting
Entero Healthcare Solutions Ltd held its 8th Annual General Meeting on August 19, 2026. Members approved all resolutions, including financial statement adoption and director re-appointments.